Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Dec 22;1(8):e38.
doi: 10.1371/journal.pctr.0010038.

Rifampicin/Cotrimoxazole/Isoniazid versus mefloquine or quinine + sulfadoxine- pyrimethamine for malaria: a randomized trial

Blaise Genton  1 , Ivo Mueller, Inoni Betuela, Gerard Casey, Meza Ginny, Michael P Alpers, John C Reeder
Affiliations

Rifampicin/Cotrimoxazole/Isoniazid versus mefloquine or quinine + sulfadoxine- pyrimethamine for malaria: a randomized trial

Blaise Genton et al. PLoS Clin Trials. .

Abstract

Objectives: Previous studies of a fixed combination including cotrimoxazole, rifampicin, and isoniazid (Cotrifazid) showed efficacy against resistant strains of Plasmodium falciparum in animal models and in small-scale human studies. We conducted a multicentric noninferiority trial to assess the safety and efficacy of Cotrifazid against drug-resistant malaria in Papua New Guinea.

Design: The trial design was open-label, block-randomised, comparative, and multicentric.

Setting: The trial was conducted in four primary care health facilities, two in urban and two in rural areas of Madang and East Sepik Province, Papua New Guinea.

Participants: Patients of all ages with recurrent uncomplicated malaria were included.

Interventions: Patients were randomly assigned to receive Cotrifazid, mefloquine, or the standard treatment of quinine with sulfadoxine-pyrimethamine (SP).

Outcome measures: Incidence of clinical and laboratory adverse events and rate of clinical and/or parasitological failure at day 14 were recorded.

Results: The safety analysis population included 123 patients assigned to Cotrifazid, 123 to mefloquine, and 123 to quinine + SP. The Cotrifazid group experienced lower overall incidence of adverse events than the other groups. Among the efficacy analysis population (72 Cotrifazid, 71 mefloquine, and 75 quinine + SP), clinical failure rate (symptoms and parasite load) on day 14 was equivalent for the three groups (0% for Cotrifazid and mefloquine; 1% for quinine + SP), but parasitological failure rate (P. falciparum asexual blood-stage) was higher for Cotrifazid than for mefloquine or quinine + SP (9% [PCR corrected 8%] versus 0% and 3%, respectively [p = 0.02]).

Conclusion: Despite what appears to be short-term clinical equivalence, the notable parasitological failure at day 14 in both P. falciparum and P. vivax makes Cotrifazid in its current formulation and regimen a poor alternative combination therapy for malaria.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Participant Flow
Figure 2
Figure 2. Time to Fever Clearance: Kaplan-Meier Analysis
Figure 3
Figure 3. Time to Clearance of All Asexual Parasites: Kaplan-Meier Analysis
See this image and copyright information in PMC

References

    1. Genton B, Baea K, Lorry K, Ginny M, Wines B, et al. Parasitological and clinical efficacy of standard treatment regimens against Plasmodium falciparum, P. vivax and P. malariae in Papua New Guinea. P N G Med J. 2005;48:141–150. - PubMed
    1. Alger NE, Spira DT, Silverman PH. Inhibition of rodent malaria in mice by rifampicin. Nature. 1970;227:381–382. - PubMed
    1. Pukrittayakamee S, Viravan C, Charoenlarp P, Yeamput C, Wilson RJ, et al. Antimalarial effects of rifampin in Plasmodium vivax malaria. Antimicrob Agents Chemother. 1994;38:511–514. - PMC - PubMed
    1. Bloland PB, Redd SC, Kazembe P, Tembenu R, Wirima JJ, et al. Co-trimoxazole for childhood febrile illness in malaria-endemic regions. Lancet. 1991;337:518–520. - PubMed
    1. Hutchinson DB, Farquhar JA. Trimethoprim-sulfamethoxazole in the treatment of malaria, toxoplasmosis, and pediculosis. Rev Infect Dis. 1982;4:419–425. - PubMed